{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:41:22Z","timestamp":1793036482659,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s10147-026-03000-7","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T05:02:10Z","timestamp":1773118930000},"page":"2566-2576","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Interleukin-1 receptor type 1 in pancreatic cancer progression and metastasis: a review"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3590-2189","authenticated-orcid":false,"given":"Kenta","family":"Saito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Denda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Nonoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromichi","family":"Murase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomokatsu","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushi","family":"Yamakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Sagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuji","family":"Takiguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"issue":"1","key":"3000_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. CA Cancer J Clin 70(1):7\u201330. https:\/\/doi.org\/10.3322\/caac.21590. (PMID: 31912902)","journal-title":"CA Cancer J Clin"},{"key":"3000_CR2","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","volume":"74","author":"L Rahib","year":"2014","unstructured":"Rahib L, Smith BD, Aizenberg R et al (2014) Projecting cancer incidence and deaths to 2030: unexpected impact of continued burden of pancreatic cancer in the United States. Cancer Res 74:2913\u20132921. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-0155. (PMID: 24840647)","journal-title":"Cancer Res"},{"key":"3000_CR3","doi-asserted-by":"publisher","first-page":"9694","DOI":"10.3748\/wjg.v22.i44.9694","volume":"22","author":"M Ilic","year":"2016","unstructured":"Ilic M, Ilic I (2016) Epidemiology of pancreatic cancer. World J Gastroenterol 22:9694\u20139705. https:\/\/doi.org\/10.3748\/wjg.v22.i44.9694. (PMID: 27956793)","journal-title":"World J Gastroenterol"},{"issue":"9","key":"3000_CR4","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1136\/gutjnl-2015-309304","volume":"64","author":"A Neesse","year":"2015","unstructured":"Neesse A, Alg\u00fcl H, Tuveson DA et al (2015) Stromal biology and therapy in pancreatic cancer: a changing paradigm. Gut 64(9):1476\u20131484. https:\/\/doi.org\/10.1136\/gutjnl-2015-309304. (PMID: 25994217)","journal-title":"Gut"},{"issue":"9","key":"3000_CR5","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41571-020-0363-5","volume":"17","author":"WJ Ho","year":"2020","unstructured":"Ho WJ, Jaffee EM, Zheng L (2020) The tumour microenvironment in pancreatic cancer\u2014clinical challenges and opportunities. Nat Rev Clin Oncol 17(9):527\u2013540. https:\/\/doi.org\/10.1038\/s41571-020-0363-5. (PMID: 32398706)","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"3000_CR6","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s10555-006-9004-4","volume":"25","author":"RN Apte","year":"2006","unstructured":"Apte RN, Dotan S, Elkabets M et al (2006) The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor\u2013host interactions. Cancer Metastasis Rev 25(3):387\u2013408. https:\/\/doi.org\/10.1007\/s10555-006-9004-4. (PMID: 17043764)","journal-title":"Cancer Metastasis Rev"},{"issue":"8","key":"3000_CR7","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/nrd3800","volume":"11","author":"CA Dinarello","year":"2012","unstructured":"Dinarello CA, Simon A, van der Meer JWM (2012) Treating inflammation by blocking Interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 11(8):633\u2013652. https:\/\/doi.org\/10.1038\/nrd3800. (PMID: 22850787)","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"3000_CR8","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.ccr.2011.03.009","volume":"19","author":"M Lesina","year":"2011","unstructured":"Lesina M, Kurkowski MU, Ludes K et al (2011) Stat3\/Socs3 activation by IL-6 trans-signaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 19(4):456\u2013469. https:\/\/doi.org\/10.1016\/j.ccr.2011.03.009. (PMID: 21481788)","journal-title":"Cancer Cell"},{"key":"3000_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2013.00289","volume":"4","author":"CA Dinarello","year":"2013","unstructured":"Dinarello CA, Novick D, Kim S et al (2013) Interleukin-18 and IL-18 binding protein. Front Immunol 4:289. https:\/\/doi.org\/10.3389\/fimmu.2013.00289. (PMID: 24115947)","journal-title":"Front Immunol"},{"key":"3000_CR10","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/nrrheum.2010.4","volume":"6","author":"C Gabay","year":"2010","unstructured":"Gabay C, Lamacchia C, Palmer G (2010) IL-1 pathways in inflammation and human diseases. Nat Rev Rheumatol 6:232\u2013241. https:\/\/doi.org\/10.1038\/nrrheum.2010.4. (PMID: 20177398)","journal-title":"Nat Rev Rheumatol"},{"key":"3000_CR11","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nm.3806","volume":"21","author":"RC Coll","year":"2015","unstructured":"Coll RC, Robertson AA, Chae JJ et al (2015) A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med 21:248\u2013255. https:\/\/doi.org\/10.1038\/nm.3806. (PMID: 25686105)","journal-title":"Nat Med"},{"key":"3000_CR12","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1158\/0008-5472.CAN-19-2080","volume":"80","author":"S Das","year":"2020","unstructured":"Das S, Shapiro B, Vucic EA et al (2020) Tumor cell-derived IL1\u03b2 promotes desmoplasia and immune suppression in pancreatic cancer. Cancer Res 80:1088\u20131101. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-2080","journal-title":"Cancer Res"},{"key":"3000_CR13","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1084\/jem.20161707","volume":"214","author":"D Daley","year":"2017","unstructured":"Daley D, Mani VR, Mohan N et al (2017) NLRP3 signaling drives macrophage-induced adaptive immune suppression in pancreatic carcinoma. J Exp Med 214:1711\u20131724. https:\/\/doi.org\/10.1084\/jem.20161707","journal-title":"J Exp Med"},{"key":"3000_CR14","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nature13490","volume":"513","author":"OR Colegio","year":"2014","unstructured":"Colegio OR, Chu NQ, Szabo AL et al (2014) Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature 513:559\u2013563. https:\/\/doi.org\/10.1038\/nature13490","journal-title":"Nature"},{"key":"3000_CR15","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1158\/2159-8290.CD-17-1134","volume":"8","author":"S Pushalkar","year":"2018","unstructured":"Pushalkar S, Hundeyin M, Daley D et al (2018) The pancreatic cancer microbiome promotes oncogenesis by induction of innate and adaptive immune suppression. Cancer Discov 8:403\u2013416. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-1134","journal-title":"Cancer Discov"},{"key":"3000_CR16","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","volume":"140","author":"SI Grivennikov","year":"2010","unstructured":"Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140:883\u2013899. https:\/\/doi.org\/10.1016\/j.cell.2010.01.025. (PMID: 20303878)","journal-title":"Cell"},{"issue":"3","key":"3000_CR17","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.immuni.2017.08.018","volume":"47","author":"Y Zhu","year":"2017","unstructured":"Zhu Y, Herndon JM, Sojka DK et al (2017) Tissue-resident macrophages in pancreatic ductal adenocarcinoma originate from embryonic hematopoiesis and promote tumor progression. Immunity 47(3):597-609.e6 (PMID: 28930663)","journal-title":"Immunity"},{"key":"3000_CR18","doi-asserted-by":"publisher","first-page":"9518","DOI":"10.1158\/0008-5472.CAN-07-0175","volume":"67","author":"CE Clark","year":"2007","unstructured":"Clark CE, Hingorani SR, Mick R et al (2007) Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res 67:9518\u20139527. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-0175. (PMID: 17909062)","journal-title":"Cancer Res"},{"key":"3000_CR19","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1158\/2159-8290.CD-18-0710","volume":"9","author":"G Biffi","year":"2019","unstructured":"Biffi G, Oni TE, Spielman B et al (2019) IL1-induced JAK\/STAT signaling is antagonized by TGF\u03b2 to shape CAF heterogeneity in pancreatic ductal adenocarcinoma. Cancer Discov 9:282\u2013301. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0710. (PMID: 30366930)","journal-title":"Cancer Discov"},{"key":"3000_CR20","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1158\/2159-8290.CD-19-0094","volume":"9","author":"E Elyada","year":"2019","unstructured":"Elyada E, Bolisetty M, Laise P et al (2019) Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts. Cancer Discov 9:1102\u20131123. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-0094. (PMID: 31197017)","journal-title":"Cancer Discov"},{"issue":"6","key":"3000_CR21","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.ccr.2014.04.005","volume":"25","author":"BC \u00d6zdemir","year":"2014","unstructured":"\u00d6zdemir BC, Pentcheva-Hoang T, Carstens JL et al (2014) Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 25(6):719\u2013734. https:\/\/doi.org\/10.1016\/j.ccr.2014.04.005. (PMID: 24856586)","journal-title":"Cancer Cell"},{"key":"3000_CR22","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aag1711","volume":"8","author":"J Park","year":"2016","unstructured":"Park J, Wysocki RW, Amoozgar Z et al (2016) Cancer cells induce metastasis-supporting neutrophil extracellular DNA traps. Sci Transl Med 8:361ra138. https:\/\/doi.org\/10.1126\/scitranslmed.aag1711. (PMID: 27798263)","journal-title":"Sci Transl Med"},{"key":"3000_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.605619","volume":"11","author":"RH Vonderheide","year":"2020","unstructured":"Vonderheide RH, Bear AS (2020) Tumor-derived myeloid cell chemoattractants and T cell exclusion in pancreatic cancer. Front Immunol 11:605619. https:\/\/doi.org\/10.3389\/fimmu.2020.605619. (PMID: 33304355)","journal-title":"Front Immunol"},{"key":"3000_CR24","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1002\/jso.21530","volume":"102","author":"D Xu","year":"2010","unstructured":"Xu D, Matsuo Y, Ma J et al (2010) Cancer cell\u2013derived interleukin-1\u03b1 promotes HGF secretion by stromal cells and enhances metastatic potential in pancreatic cancer cells. J Surg Oncol 102:469\u2013477. https:\/\/doi.org\/10.1002\/jso.21530. (PMID: 20872950)","journal-title":"J Surg Oncol"},{"issue":"2","key":"3000_CR25","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.jss.2008.04.040","volume":"153","author":"Y Matsuo","year":"2009","unstructured":"Matsuo Y, Sawai H, Ochi N et al (2009) Interleukin-1\u03b1 secreted by pancreatic cancer cells promotes angiogenesis and its therapeutic implications. J Surg Res 153(2):274\u2013281. https:\/\/doi.org\/10.1016\/j.jss.2008.04.040. (PMID: 18952231)","journal-title":"J Surg Res"},{"key":"3000_CR26","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1158\/1078-0432.CCR-17-2092","volume":"24","author":"JF Rossi","year":"2018","unstructured":"Rossi JF, Lu ZY, Jourdan M et al (2018) Interleukin-1\u03b1s a therapeutic target. Clin Cancer Res 24:2442\u20132450 (PMID: 29598817)","journal-title":"Clin Cancer Res"},{"key":"3000_CR27","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1016\/S0140-6736(17)32247-X","volume":"390","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, MacFadyen JG, Thuren T et al (2017) Effect of interleukin-1\u03b2 inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet 390:1833\u20131842. https:\/\/doi.org\/10.1016\/S0140-6736(17)32247-X. (PMID: 28855077)","journal-title":"Lancet"},{"key":"3000_CR28","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.3389\/fimmu.2018.01878","volume":"9","author":"D Kabacaoglu","year":"2018","unstructured":"Kabacaoglu D, Ruess DA, Ai J et al (2018) Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: current status and future perspectives. Front Immunol 9:1617 (PMID: 30038678)","journal-title":"Front Immunol"},{"issue":"1","key":"3000_CR29","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.immuni.2019.06.025","volume":"51","author":"FR Greten","year":"2019","unstructured":"Greten FR, Grivennikov SI (2019) Inflammation and cancer: triggers, mechanisms, and consequences. Immunity 51(1):27\u201341. https:\/\/doi.org\/10.1016\/j.immuni.2019.06.025. (PMID: 31315034)","journal-title":"Immunity"},{"key":"3000_CR30","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41575-018-0005-x","volume":"15","author":"JP Neoptolemos","year":"2018","unstructured":"Neoptolemos JP, Kleeff J, Michl P et al (2018) Therapeutic developments in pancreatic cancer: current and future perspectives. Nat Rev Gastroenterol Hepatol 15:333\u2013348. https:\/\/doi.org\/10.1038\/s41575-018-0005-x. (PMID: 29717230)","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3000_CR31","doi-asserted-by":"publisher","first-page":"C706","DOI":"10.1152\/ajpcell.00626.2008","volume":"297","author":"W Li","year":"2009","unstructured":"Li W, Moylan JS, Chambers MA et al (2009) Interleukin-1 stimulates catabolism in C2C12 myotubes. Am J Physiol Cell Physiol 297:C706\u2013C714. https:\/\/doi.org\/10.1152\/ajpcell.00626.2008","journal-title":"Am J Physiol Cell Physiol"},{"key":"3000_CR32","doi-asserted-by":"publisher","first-page":"C762","DOI":"10.1152\/ajpcell.00361.2013","volume":"306","author":"CL Wu","year":"2014","unstructured":"Wu CL, Cornwell EW, Jackman RW et al (2014) NF-\u03baB but not FoxO sites in the MuRF1 promoter are required for transcriptional activation in disuse muscle atrophy. Am J Physiol Cell Physiol 306:C762\u2013C767. https:\/\/doi.org\/10.1152\/ajpcell.00361.2013","journal-title":"Am J Physiol Cell Physiol"},{"key":"3000_CR33","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1194\/jlr.M086504","volume":"59","author":"N Issa","year":"2018","unstructured":"Issa N, Lachance G, Bellmann K et al (2018) Cytokines promote lipolysis in 3T3-L1 adipocytes through induction of NADPH oxidase 3 expression and superoxide production. J Lipid Res 59:2321\u20132328. https:\/\/doi.org\/10.1194\/jlr.M086504","journal-title":"J Lipid Res"},{"key":"3000_CR34","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1210\/endo.130.1.1370149","volume":"130","author":"KR Feingold","year":"1992","unstructured":"Feingold KR, Doerrler W, Dinarello CA et al (1992) Stimulation of lipolysis in cultured fat cells by tumor necrosis factor, interleukin-1, and the interferons is blocked by inhibition of prostaglandin synthesis. Endocrinology 130:10\u201316. https:\/\/doi.org\/10.1210\/endo.130.1.1370149","journal-title":"Endocrinology"},{"key":"3000_CR35","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1158\/1078-0432.CCR-14-1860","volume":"21","author":"GL Beatty","year":"2015","unstructured":"Beatty GL, Gladney WL (2015) Immune escape mechanisms as a guide for cancer immunotherapy. Clin Cancer Res 21:687\u2013692. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-1860. (PMID: 25501578)","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3000_CR36","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1093\/carcin\/bgp272","volume":"31","author":"AJ Schetter","year":"2010","unstructured":"Schetter AJ, Heegaard NH, Harris CC (2010) Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis 31(1):37\u201349. https:\/\/doi.org\/10.1093\/carcin\/bgp272. (PMID: 19955394)","journal-title":"Carcinogenesis"},{"key":"3000_CR37","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1038\/s41416-018-0246-z","volume":"119","author":"D Melisi","year":"2018","unstructured":"Melisi D, Garcia-Carbonero R, Macarulla T et al (2018) Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer. Br J Cancer 119:1208\u20131214. https:\/\/doi.org\/10.1038\/s41416-018-0246-z","journal-title":"Br J Cancer"},{"key":"3000_CR38","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s10637-020-01044-8","volume":"39","author":"C Kenney","year":"2021","unstructured":"Kenney C, Kunst T, Webb S et al (2021) Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRASG12R-mutant pancreatic ductal adenocarcinoma. Invest New Drugs 39:821\u2013828. https:\/\/doi.org\/10.1007\/s10637-020-01044-8","journal-title":"Invest New Drugs"},{"key":"3000_CR39","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1038\/nm.4123","volume":"22","author":"H Jiang","year":"2016","unstructured":"Jiang H, Hegde S, Knolhoff BL et al (2016) Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. Nat Med 22:851\u2013860. https:\/\/doi.org\/10.1038\/nm.4123. (PMID: 27376576)","journal-title":"Nat Med"},{"issue":"6","key":"3000_CR40","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/S1470-2045(14)70155-X","volume":"15","author":"DS Hong","year":"2014","unstructured":"Hong DS, Hui D, Bruera E et al (2014) MABp1, a first-in-class true human antibody targeting interleukin-1\u03b1 in refractory cancers: an open-label, phase 1 dose-escalation and expansion study. Lancet Oncol 15(6):656\u2013666. https:\/\/doi.org\/10.1016\/S1470-2045(14)70155-X. (PMID: 24746841)","journal-title":"Lancet Oncol"},{"key":"3000_CR41","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1056\/NEJMe0811014","volume":"360","author":"CA Dinarello","year":"2009","unstructured":"Dinarello CA (2009) Interleukin-1\u03b2 and the autoinflammatory diseases. N Engl J Med 360:2467\u20132470. https:\/\/doi.org\/10.1056\/NEJMe0811014. (PMID: 19494224)","journal-title":"N Engl J Med"},{"key":"3000_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01561-6","volume":"17","author":"P Farhangnia","year":"2024","unstructured":"Farhangnia P, Khorramdelazad H, Nickho H et al (2024) Current and future immunotherapeutic approaches in pancreatic cancer treatment. J Hematol Oncol 17:40. https:\/\/doi.org\/10.1186\/s13045-024-01561-6","journal-title":"J Hematol Oncol"},{"key":"3000_CR43","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2024.13283","volume":"30","author":"H Li","year":"2024","unstructured":"Li H, Liu D, Li K et al (2024) Pancreatic stellate cells and the interleukin family: Linking fibrosis and immunity to pancreatic ductal adenocarcinoma. Mol Med Rep 30:159. https:\/\/doi.org\/10.3892\/mmr.2024.13283","journal-title":"Mol Med Rep"},{"key":"3000_CR44","doi-asserted-by":"publisher","first-page":"589","DOI":"10.3390\/cancers17040589","volume":"17","author":"D Sherpally","year":"2025","unstructured":"Sherpally D, Patel H, Al-Rawi D et al (2025) Advancing immunotherapy in pancreatic cancer: a brief update. Cancers (Basel) 17:589. https:\/\/doi.org\/10.3390\/cancers17040589","journal-title":"Cancers (Basel)"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03000-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03000-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03000-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:05:15Z","timestamp":1793034315000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03000-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":44,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["3000"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-03000-7","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]},"assertion":[{"value":"23 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}